{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:40:09Z","timestamp":1793284809927,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T00:00:00Z","timestamp":1739664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.euo.2025.02.006","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T11:22:17Z","timestamp":1745839337000},"page":"782-791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Total and Regional Changes in Body Composition in Metastatic Hormone-sensitive Prostate Cancer Patients Randomized to Receive Androgen Deprivation + Enzalutamide \u00b1 Zoledronic Acid. The BONENZA Study"],"prefix":"10.1016","volume":"8","author":[{"given":"Martina","family":"Buffoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Dalla Volta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Valcamonico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bergamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Caramella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"D\u2019Apollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Zivi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piera","family":"Sepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Del Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzia","family":"Di Meo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Foti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Zamboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Lucchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Maroldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Lagan\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ravanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Zamparini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Zacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazareno","family":"Suardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.02.006_b0005","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.02.006_b0010","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.02.006_b0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.02.006_b0020","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.02.006_b0025","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.02.006_b0030","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.02.006_b0035","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.02.006_b0040","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.02.006_b0045","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.02.006_b0050","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration\u2013resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.02.006_b0055","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration\u2013resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.02.006_b0060","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.02.006_b0065","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.02.006_b0070","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.eururo.2021.06.023","article-title":"Should patients with high-risk localised or locally advanced prostate cancer receive abiraterone acetate in addition to androgen deprivation therapy? Update on a planned analysis of the STAMPEDE trial","volume":"80","author":"Attard","year":"2021","journal-title":"Eur Urol"},{"issue":"Suppl 1","key":"10.1016\/j.euo.2025.02.006_b0075","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/jsm.12036","article-title":"Androgen deprivation therapy impact on quality of life and cardiovascular health, monitoring therapeutic replacement","volume":"10","author":"Trost","year":"2013","journal-title":"J Sex Med"},{"key":"10.1016\/j.euo.2025.02.006_b0080","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0022-5347(05)64985-3","article-title":"Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy","volume":"167","author":"Berruti","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.02.006_b0085","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.urology.2003.10.063","article-title":"Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer","volume":"63","author":"Smith","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.euo.2025.02.006_b0090","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.euo.2025.02.006_b0095","article-title":"Body composition and metastatic prostate cancer survivorship","volume":"27","author":"Coletta","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.euo.2025.02.006_b0100","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.juro.2017.08.103","article-title":"Long-term antitumor activity and safety of enzalutamide monotherapy in hormone na\u00efve prostate cancer: 3-year open label followup results","volume":"199","author":"Tombal","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.02.006_b0105","article-title":"Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer","volume":"25","author":"Fischer","year":"2020","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.euo.2025.02.006_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2023.09.004","article-title":"Profiling of skeletal muscle and adipose tissue depots in men with advanced prostate cancer receiving different forms of androgen deprivation therapy","volume":"57","author":"Blow","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2025.02.006_b0115","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.eururo.2024.05.004","article-title":"Whole-body diffusion-weighted magnetic resonance imaging for assessment of the bone response rate in patients with metastatic hormone-sensitive prostate cancer receiving enzalutamide","volume":"86","author":"Dalla Volta","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.02.006_b0120","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.02.006_b0125","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.02.006_b0130","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.clnu.2021.11.014","article-title":"Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement","volume":"41","author":"Donini","year":"2022","journal-title":"Clin Nutr"},{"key":"10.1016\/j.euo.2025.02.006_b0135","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1210\/jcem.86.9.7851","article-title":"The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer","volume":"86","author":"Smith","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.euo.2025.02.006_b0140","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41391-021-00474-6","article-title":"Is BMI a reliable prognostic parameter in metastatic prostate cancer patients?","volume":"25","author":"Caramella","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2025.02.006_b0145","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40618-023-02150-z","article-title":"Heterogeneity in regional changes in body composition induced by androgen deprivation therapy in prostate cancer patients: potential impact on bone health\u2014the BLADE study","volume":"47","author":"Dalla Volta","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.euo.2025.02.006_b0150","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/j.1550-8528.1993.tb00614.x","article-title":"Visceral Obesity: A \u201ccivilization syndrome.\u201d","volume":"1","author":"Bj\u00f6rntorp","year":"1993","journal-title":"Obes Res"},{"key":"10.1016\/j.euo.2025.02.006_b0155","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jsbmb.2007.09.001","article-title":"Androgens and body fat distribution","volume":"108","author":"Blouin","year":"2008","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.euo.2025.02.006_b0160","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/ijo.2012.95","article-title":"Ethnic and sex differences in body fat and visceral and subcutaneous adiposity in children and adolescents","volume":"36","author":"Staiano","year":"2012","journal-title":"Int J Obes"},{"key":"10.1016\/j.euo.2025.02.006_b0165","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1038\/nutd.2015.6","article-title":"Comparative effect of intraduodenal and intrajejunal glucose infusion on the gut-incretin axis response in healthy males","volume":"5","author":"Wu","year":"2015","journal-title":"Nutr Diabetes"},{"key":"10.1016\/j.euo.2025.02.006_b0170","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.3390\/ijms21103607","article-title":"Physical exercise and myokines: relationships with sarcopenia and cardiovascular complications","volume":"21","author":"Barbalho","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.euo.2025.02.006_b0175","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1185221","article-title":"Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management","volume":"14","author":"Wei","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.euo.2025.02.006_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164385","article-title":"Development of novel methods to define deficits in appendicular lean mass relative to fat mass","volume":"11","author":"Weber","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.euo.2025.02.006_b0185","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/jcsm.12613","article-title":"Validation of a description of sarcopenic obesity defined as excess adiposity and low lean mass relative to adiposity","volume":"11","author":"Baker","year":"2020","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.euo.2025.02.006_b0190","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1210\/clinem\/dgac489","article-title":"Effect of degarelix administration on bone health in prostate cancer patients without bone metastases. The Blade study","volume":"107","author":"Palumbo","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.euo.2025.02.006_b0195","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11657-022-01087-9","article-title":"Sarcopenic obesity defined by visceral adiposity was associated with osteoporotic vertebral fracture","volume":"17","author":"Chen","year":"2022","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.euo.2025.02.006_b0200","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1017\/S0007114520002172","article-title":"Sarcopenic obesity in ageing: cardiovascular outcomes and mortality","volume":"124","author":"Atkins","year":"2020","journal-title":"Br J Nutr"},{"key":"10.1016\/j.euo.2025.02.006_b0205","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.bbrc.2016.10.112","article-title":"Ibandronate concomitantly blocks immobilization-induced bone and muscle atrophy","volume":"480","author":"Watanabe","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.euo.2025.02.006_b0210","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.nmd.2015.09.015","article-title":"Positive effects of bisphosphonates on bone and muscle in a mouse model of Duchenne muscular dystrophy","volume":"26","author":"Yoon","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.euo.2025.02.006_b0215","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.afos.2015.07.005","article-title":"Effect of alendronate on muscle mass: investigation in patients with osteoporosis","volume":"1","author":"Harada","year":"2015","journal-title":"Osteoporos Sarcopenia"},{"key":"10.1016\/j.euo.2025.02.006_b0220","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2011.38.8850","article-title":"Sarcopenia during androgen-deprivation therapy for prostate cancer","volume":"30","author":"Smith","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.02.006_b0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13679-020-00419-5","article-title":"Drugs affecting body weight, body fat distribution, and metabolic function-mechanisms and possible therapeutic or preventive measures: an update","volume":"10","author":"Verhaegen","year":"2021","journal-title":"Curr Obes Rep"},{"key":"10.1016\/j.euo.2025.02.006_b0230","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5507\/bp.2020.058","article-title":"Body composition changes during and after curative chemotherapy in patients with testicular cancer","volume":"166","author":"Semerad","year":"2022","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"10.1016\/j.euo.2025.02.006_b0235","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1016\/j.clnu.2020.11.020","article-title":"Chemotherapy negatively impacts body composition, physical function and metabolic profile in patients with breast cancer","volume":"40","author":"Godinho-Mota","year":"2021","journal-title":"Clin Nutr"},{"key":"10.1016\/j.euo.2025.02.006_b0240","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10549-023-07095-8","article-title":"Is weight gain preventable in women with early breast cancer undergoing chemotherapy? A real-world study on dietary pattern, physical activity, and body weight before and after chemotherapy","volume":"202","author":"Pedersini","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.euo.2025.02.006_b0245","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s11912-023-01447-9","article-title":"Role of body composition in the prediction of skeletal fragility induced by hormone deprivation therapies in cancer patients","volume":"25","author":"Dalla Volta","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.euo.2025.02.006_b0250","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1249\/MSS.0000000000003452","article-title":"Resistance exercise and skeletal muscle-related outcomes in patients with cancer: a systematic review","volume":"56","author":"Kang","year":"2024","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.euo.2025.02.006_b0255","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1249\/MSS.0000000000002116","article-title":"Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable","volume":"51","author":"Campbell","year":"2019","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.euo.2025.02.006_b0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0263918","article-title":"The effects of exercise on body composition of prostate cancer patients receiving androgen deprivation therapy: an update systematic review and meta-analysis","volume":"17","author":"Shao","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.euo.2025.02.006_b0265","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO clinical practice guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann Oncol."},{"key":"10.1016\/j.euo.2025.02.006_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103484","article-title":"Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies","volume":"9","author":"Cursano","year":"2024","journal-title":"ESMO Open"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125000422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125000422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T16:55:40Z","timestamp":1748451340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125000422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2588931125000422"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.02.006","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Total and Regional Changes in Body Composition in Metastatic Hormone-sensitive Prostate Cancer Patients Randomized to Receive Androgen Deprivation + Enzalutamide \u00b1 Zoledronic Acid. The BONENZA Study","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}